Federal judge denies preliminary injunction in tirzepatide compounding case
Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide from its official shortage list.
The US District Court for the Northern District of Texas denied …
Novo Nordisk’s Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more…
Ozempic is increasingly being linked to vision loss. What’s the truth?
Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why
Makers of Wegovy and Zepbound cut prices for those without insurance
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance.
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
FRIDAY, March 7, 2025 — The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Novo Nordisk, the Danish company behind Wegovy…
Is Intermittent Fasting Worth Considering for Your Patients?
Studies suggest types of fasting can lead to moderate weight loss and other health benefits in overweight and obese people, but only some doctors use it. Medscape Medical News
Naturally occurring molecule rivals Ozempic in weight loss, sidesteps side effects
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as Ozempic—in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of the drug’s side effects, such as nausea, constipation and significant loss of muscle mass.